About AAVANTIBio
AAVANTIBio is a company based in Gainesville (United States) founded in 2017 was acquired by Solid Biosciences in September 2022.. AAVANTIBio has raised $107 million across 1 funding round from investors including Solid Biosciences, Sarepta Therapeutics and Bain Capital. AAVANTIBio operates in a competitive market with competitors including Jazz Pharmaceuticals, Senti Biosciences, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Gainesville, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$107 M (USD)
in 1 rounds
-
Latest Funding Round
$107 M (USD), Series A
Oct 22, 2020
-
Investors
Solid Biosciences
& 4 more
-
Employee Count
Employee Count
-
Acquired by
Solid Biosciences
(Sep 30, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of AAVANTIBio
AAVANTIBio has successfully raised a total of $107M through 1 strategic funding round. The most recent funding activity was a Series A round of $107 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $107.0M
-
First Round
First Round
(22 Oct 2020)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2020 | Amount | Series A - AAVANTIBio | Valuation | Perceptive Advisors , Bain Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AAVANTIBio
AAVANTIBio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Solid Biosciences, Sarepta Therapeutics and Bain Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Debt and equity investments are pursued across multiple sectors.
|
Founded Year | Domain | Location | |
|
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AAVANTIBio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AAVANTIBio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aavantibio Comparisons
Competitors of AAVANTIBio
AAVANTIBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Senti Biosciences, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aavantibio
Frequently Asked Questions about AAVANTIBio
When was AAVANTIBio founded?
AAVANTIBio was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Where is AAVANTIBio located?
AAVANTIBio is headquartered in Gainesville, United States.
Is AAVANTIBio a funded company?
AAVANTIBio is a funded company, having raised a total of $107M across 1 funding round to date. The company's 1st funding round was a Series A of $107M, raised on Oct 22, 2020.
What does AAVANTIBio do?
AAVANTIBio was founded in 2017 and is based in Gainesville, United States. Focus is placed on biotechnology within the gene therapy sector. Gene-editing technologies are developed to target fatal neuromuscular conditions. Operations center on AAV-mediated gene transfer approaches, with the lead program directed at Friedreichs ataxia. Research and development activities aim to address unmet needs in disease treatment through innovative delivery methods.
Who are the top competitors of AAVANTIBio?
AAVANTIBio's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Who are AAVANTIBio's investors?
AAVANTIBio has 5 investors. Key investors include Solid Biosciences, Sarepta Therapeutics, Bain Capital, RA Capital, and Perceptive Advisors.